Methods of treating impaired glucose metabolism via administration of algal biomass

Patent metadata

Field	Value
Publication number	US-9345730-B2
Application number	US-201414266715-A
Country	US
Kind code	B2
Filing date	Apr 30, 2014
Priority date	Mar 3, 2009
Publication date	May 24, 2016
Grant date	May 24, 2016

Abstract

The invention is directed to methods of using Chlorella protothecoides microalgal biomass in the treatment of individuals having impaired glucose metabolism. In some cases, the patient has impaired fasting glucose, impaired glucose tolerance, or diabetes. In some methods, algal biomass is used to reduce blood glucose and/or body fat in a subject, or to increase the relative abundance of beneficial gut microflora in a subject. In preferred embodiments, the biomass is derived from Chlorella protothecoides cultures grown heterotrophically in which the algal cells comprise at least 15% algal oil by dry weight.

First claim

What is claimed is:

1. A method of increasing the relative abundance of beneficial gut microflora in a subject, comprising determining the subject would benefit from a greater abundance of beneficial gut microflora and then administering to the subject an effective regime of Chlorella protothecoides microalgal biomass comprising at least 15% algal oil by dry weight, whereby the relative abundance of beneficial gut microflora is increased as compared to the relative abundance before administering the regime.

2. The method of claim 1 , wherein the algal biomass contains 25-75%, of algal oil by dry weight.

3. The method of claim 1 , wherein at least 50% by weight of the algal oil is monounsaturated oil.

4. The method of claim 1 , wherein less than 5% by weight of the algal oil is docosahexanoic acid (DHA).

5. The method of claim 1 , wherein the algal oil is predominantly encapsulated in cells of the biomass.

6. The method of claim 1 , wherein the biomass is administered as a homogenate.

7. The method of claim 1 , wherein the regime comprises administering the algal biomass at a dose of 1-20% of food by weight or calories.

8. The method of claim 1 , wherein the algal biomass is administered daily for at least a week.

9. The method of claim 1 , wherein the algal biomass is administered with at least one other edible ingredient as a food composition.

10. The method of claim 1 , wherein the regime additionally lowers the percentage fat of total body weight in the subject relative to the percentage before the administering step.

11. The method of claim 1 , wherein the algal biomass is derived from Chlorella protothecoides grown heterotrophically.

12. The method of claim 11 , wherein the Chlorella protothecoides is grown in a culture medium including a feedstock comprising at least one carbon substrate selected from the group consisting of a depolymerized cellulosic material, a 5-carbon sugar, and a 6-carbon sugar.

13. The method of claim 1 , wherein the algal biomass is administered in the form of a tablet or capsule.

14. The method of claim 1 , wherein the algal biomass is administered in the form of a food product.

Assignees

• Solazyme Inc
• Univ Manitoba

Inventors

• Brinkmann David
• Day Anthony G
• Jones Peter J H
• Harding Scott

Classifications

• A61P3/08

  for glucose homeostasis (pancreatic hormones A61P5/48) · CPC title

• A61K36/02 Primary

  Algae · CPC title

• A61P3/04

  Anorexiants; Antiobesity agents · CPC title

• A61K31/202

  having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557) · CPC title

• A23L33/105

  Plant extracts, their artificial duplicates or their derivatives · CPC title